

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-31 (Canceled)

32. (Original) A pharmaceutical composition comprising, by weight:

a) from about 2% to about 8% 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof;

b) lactose from about 32% to about 38%;

c) microcrystalline cellulose from about 32% to about 38%;

d) pregelatinized starch from about 12% to about 16%;

e) ascorbic acid from about 1% to about 2%;

f) sodium lauryl sulfate from about 1% to about 2%;

g) sodium starch glycolate from about 4% to about 8%;

h) silicon dioxide from about 0.1% to about 0.2%; and

i) magnesium stearate from about 0.3% to about 0.7%.

33. (Original) A pharmaceutical composition comprising, by weight:

a) from about 0.1% to about 25% 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl)-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof;

b) from about 20% to about 80% lactose;

c) from about 4% to about 40% pregelatinized starch;

d) from about 0.2% to about 5% sodium lauryl sulfate;

e) from about 0.5% to about 15% ascorbic acid;

f) from about 0.1% to about 10% silicon dioxide; and

g) from about 0.2% to about 10% magnesium stearate.

34. (Original) A pharmaceutical composition of Claim 33 comprising, by weight:

- a) from about 5% to about 18% 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or 2-(4-Hydroxy-phenyl)-3-methyl-1-(4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol, or a pharmaceutically acceptable salt thereof;
- b) from about 47% to about 77% lactose;
- c) from about 25% to about 35% pregelatinized starch;
- d) from about 1% to about 2% sodium lauryl sulfate;
- e) from about 1% to about 3% ascorbic acid;
- f) from about 0.1% to about 0.5% silicon dioxide; and
- g) from about 0.2% to about 0.5% magnesium stearate.

35. (Previously presented) A pharmaceutical composition comprising:

- a) an active pharmacological agent from about 0.1% to about 25% by weight of the pharmaceutical formulation, wherein the active pharmacological agent is 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol or a pharmaceutically acceptable salt thereof;
- b) a filler and disintegrant component comprising from about 20% to about 80% by weight of the pharmaceutical formulation;
- c) a disintegrant component comprising from about 4% to about 40% by weight of the pharmaceutical formulation;
- d) a wetting agent comprising from about 0.2% to about 5% of the pharmaceutical formulation;
- e) an antioxidant comprising from about 0.5% to about 15% of the pharmaceutical formulation;
- f) a glidant comprising from about 0.1% to about 10% of the pharmaceutical formulation; and
- g) a lubricant comprising from about 0.2% to about 10% of the pharmaceutical formulation.

36. (Previously presented) The pharmaceutical composition of claim 35 wherein the filler and disintegrant component comprises lactose and microcrystalline cellulose.
37. (Previously presented) The pharmaceutical composition of claim 35 wherein the disintegrant component comprises pregelatinized starch.
38. (Previously presented) The pharmaceutical composition of claim 35 wherein the filler and disintegrant component comprises lactose and microcrystalline cellulose; and the disintegrant component comprises pregelatinized starch.
39. (Previously presented) The pharmaceutical composition of claim 38 wherein the antioxidant comprises ascorbic acid.
40. (Previously presented) The pharmaceutical composition of claim 38 wherein the lubricant comprises magnesium stearate.
41. (Previously presented) The pharmaceutical composition of claim 38 wherein the antioxidant comprises ascorbic acid; and the lubricant comprises magnesium stearate.
42. (Previously presented) The pharmaceutical composition of claim 41 wherein the glidant comprises silicon dioxide; and the wetting agent comprises sodium lauryl sulfate.
- 43-66 (Canceled)